Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies

@article{Pratley2009AlogliptinUI,
  title={Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies},
  author={Richard E. Pratley and Th{\'e}r{\`e}se McCall and Penny Fleck and Craig A. Wilson and QaisA. Mekki},
  journal={Journal of the American Geriatrics Society},
  year={2009},
  volume={57}
}
OBJECTIVES: To compare the efficacy and safety of alogliptin, a dipeptidyl peptidase‐4 (DPP‐4) enzyme inhibitor, in elderly (≥65) and younger (<65) patients with type 2 diabetes mellitus. 
View on Wiley
ncbi.nlm.nih.gov
82 Citations
Highly Influential Citations
4
Background Citations
23
Methods Citations
5
Results Citations
7

82 Citations

Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double‐blind, randomized, 1‐year study
To prospectively evaluate the efficacy and safety of alogliptin versus glipizide in elderly patients with type 2 diabetes mellitus (T2DM) over 1 year of treatment.
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study
To evaluate the long‐term durability of the efficacy of alogliptin compared with glipizide in combination with metformin in people with type 2 diabetes inadequately controlled on stable‐dose…
Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double‐blind placebo‐controlled Phase 3 study in mainland China, Taiwan, and Hong Kong
This study determined the efficacy and safety of once‐daily oral alogliptin in patients from mainland China, Taiwan, and Hong Kong with type 2 diabetes mellitus.
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials
Aim: To report the experience with vildagliptin in a patient population with type 2 diabetes mellitus (T2DM) ≥75 years.
Dipeptidyl peptidase‐4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta‐analysis of randomized controlled trials
Aim: We assessed the efficacy of dipeptidyl peptidase‐4 (DPP‐4) inhibitors vildagliptin, sitagliptin, saxagliptin and alogliptin to reach the haemoglobin HbA1c target of <7% in people with type 2…
Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study
TLDR
To evaluate the efficacy and safety of alogliptin added to treatment with glimepiride, a new drug is developed that combines the former and the former for the treatment of central nervous system disorders.
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension study
TLDR
Patients with type 2 diabetes who achieved inadequate glycaemic control on pioglitazone plus diet/exercise are studied to assess the efficacy and safety of alogliptin added to piog Litazone versus piog litazone monotherapy.
Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin
 This paper discusses the possibilities and benefits of early combination therapy and the application features of a fixed-dose combination of metformin and alogliptin (Vipdomet®) in the treatment of…
Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials
TLDR
The aim of this study is the assessment of predictors of response to DPP‐4 inhibitors.
Alogliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
TLDR
Clinical trial data with alogliptin demonstrate clinical efficacy in terms of A1C and FPG reductions when used both as monotherapy and in combination with other oral antidiabetic medications.
...
...

References

SHOWING 1-10 OF 34 REFERENCES
Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
Aim:  To evaluate the efficacy and safety of alogliptin, a potent and highly selective dipeptidyl peptidase‐4 (DPP‐4) inhibitor, in combination with glyburide in patients with type 2 diabetes…
Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
TLDR
To assess the efficacy and safety of a 24‐week treatment with sitagliptin, a highly selective once‐daily oral dipeptidyl peptidase‐4 (DPP‐4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control while on glimepiride alone or in combination with metformin.
Individual Sulfonylureas and Serious Hypoglycemia in Older People
TLDR
To compare the risk of serious hypoglycemia associated with the use of individual sulfonylureas in older people, a large number of older people with a history of diabetes and obesity are considered to be at risk.
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
TLDR
Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4) and related quinazolinone-based DPP-4 inhibitors provide sustained reduction of plasma D PP-4 activity and a lowering of blood glucose in animal models of diabetes.
Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP‐4 inhibitors
TLDR
Newer agents based on enhancing incretin activity, including the glucagon‐like peptide‐1 mimetics exenatide and liraglutide and the oral dipeptidyl peptidase‐4 inhibitors sitagli leptin and vildagliptin, may offer particular advantages in elderly patients with diabetes.
Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus
TLDR
A systematic review was commissioned to summarize the comparative benefits and harms of oral agents that are used to treat type 2 diabetes and selected studies that reported on major clinical outcomes or any of the following intermediate end points or adverse events.
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
TLDR
Dipeptidyl peptidase-4 inhibitors appear to improve islet function and may modify the course of diabetes; this, however, must be confirmed with long-term controlled studies to demonstrate sustained glycemic control that translates into β-cell preservation.
DPP‐4 inhibitors and their potential role in the management of type 2 diabetes
  • A. Barnett
  • Medicine, Biology
    International journal of clinical practice
  • 2006
TLDR
The leading DPP‐4 inhibitors have shown clinically significant HbA1c reductions up to 1 year of treatment and offer many potential advantages over existing diabetes therapies including a low risk of hypoglycaemia, no effect on body weight, and the potential for the regeneration and differentiation of pancreatic β‐cells.
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
TLDR
Delayed elimination of GLP-1 and GIP in renal insufficiency may influence the pharmacokinetics and pharmacodynamics of dipeptidyl peptidase IV-resistant incretin derivatives to be used for the treatment of patients with type 2 diabetes.
Effects of Intensive Glucose Lowering in Type 2 Diabetes
...
...